On 25 July 2006, Dr. Terry O’Brien, Chief Executive and director of the Company, informed the Company that today he has sold 760,975 ordinary shares of 0.5p each in the Company at 20.5 pence per share. Dr O’Brien’s pension fund subsequently bought today 760,975 ordinary shares of 0.5p each at 20.5 pence per share.

As a consequence of his sale and re-purchase, Dr O’Brien’s interest in the share capital of the Company remains at 10,109,577 shares representing approximately 8.56 % of the Company’s issued share capital.

Notes to Editors

About LiDCO Plc
LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO's technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London where the Company maintains a research base.

The Company's manufacturing facility is in Hoxton, London N1 and its current products are:

• LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume;
• LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner.

Distribution Network
The Company has now achieved registration of its products in 17 markets in Europe, the USA, Brazil and Japan. It sells direct in the UK and USA, and elsewhere through a worldwide network of specialty critical care distributors.